Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. Vericel Corporation was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in November 2014. The company was incorporated in 1989 and is headquartered in Burlington, Massachusetts.…
Vericel to Present at the Stephens Annual Investment Conference on Wednesday, November 18, 2026
Vericel (NASDAQ: VCEL) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 398 employees.
The shares were at 57.52 USD on 20 November 2026, up 48.4% over 52 weeks. Its 52-week range is 28.95 USD to 59.75 USD: the price is 3.7% below the high and 98.7% above the low.
At a market capitalisation of 2.94B USD, it trades at 89.9 times trailing earnings and 61.1 times forward earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.1, a premium of 171% for VCEL.
Vericel reports return on equity of 4.7%, an operating margin of 8.3% and revenue up 26.5% year over year.
It holds more cash than debt, a net cash position of 79.12M USD. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health. 7 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 65.43 USD is 13.7% above the current price. The next earnings report is expected on 25 February 2027.